Michael A Schwarzschild1, Eric A Macklin2, Rachit Bakshi2, Shamik Battacharyya2, Robert Logan2, Alberto J Espay2, Albert Y Hung2, Grace Bwala2, Christopher G Goetz2, David S Russell2, John L Goudreau2, Sotirios A Parashos2, Marie H Saint-Hilaire2, Alice Rudolph2, Joshua M Hare2, Gary C Curhan2, Alberto Ascherio2. 1. From the Departments of Neurology (M.A.S., R.B., S.B., R.L., A.Y.H., G.B.) and Medicine (E.A.M.), Massachusetts General Hospital, Boston; University of Cincinnati (A.J.E.), OH; Rush University (C.G.G.), Chicago, IL; Michigan State University (J.L.G.), East Lansing; Struthers Parkinson's Center (S.A.P.), Minneapolis, MN; Boston University (M.H.S.-H.), MA; University of Rochester (A.R.), NY; University of Miami (J.M.H.), FL; Brigham and Women's Hospital (G.C.C.), Boston, MA; Yale University School of Medicine (D.S.R.), New Haven, CT; and Department of Nutrition (A.A.), Harvard School of Public Health, Boston, MA. michaels@helix.mgh.harvard.edu. 2. From the Departments of Neurology (M.A.S., R.B., S.B., R.L., A.Y.H., G.B.) and Medicine (E.A.M.), Massachusetts General Hospital, Boston; University of Cincinnati (A.J.E.), OH; Rush University (C.G.G.), Chicago, IL; Michigan State University (J.L.G.), East Lansing; Struthers Parkinson's Center (S.A.P.), Minneapolis, MN; Boston University (M.H.S.-H.), MA; University of Rochester (A.R.), NY; University of Miami (J.M.H.), FL; Brigham and Women's Hospital (G.C.C.), Boston, MA; Yale University School of Medicine (D.S.R.), New Haven, CT; and Department of Nutrition (A.A.), Harvard School of Public Health, Boston, MA.
Abstract
OBJECTIVE: To investigate whether women and men with Parkinson disease (PD) differ in their biochemical and clinical responses to long-term treatment with inosine. METHODS: The Safety of Urate Elevation in Parkinson's Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation for up to 2 years. Parkinsonism, serum urate, and plasma antioxidant capacity were measured at baseline and repeatedly on treatment; CSF urate was assessed once, at 3 months. Here in secondary analyses results are stratified by sex. RESULTS: Inosine produced an absolute increase in average serum urate from baseline that was 50% greater in women (3.0 mg/dL) than in men (2.0 mg/dL), consistent with expected lower baseline levels in women. Similarly, only among women was CSF urate significantly greater on mild or moderate inosine (+87% [p < 0.001] and +98% [p < 0.001], respectively) than on placebo (in contrast to men: +10% [p = 0.6] and +14% [p = 0.4], respectively). Women in the higher inosine dosing group showed a 7.0 Unified Parkinson's Disease Rating Scale (UPDRS) points/year lower rate of decline vs placebo (p = 0.01). In women, slower rates of UPDRS change were associated with greater increases in serum urate (r = -0.52; p = 0.001), and with greater increases in plasma antioxidant capacity (r = -0.44; p = 0.006). No significant associations were observed in men. CONCLUSIONS: Inosine produced greater increases in serum and CSF urate in women compared to men in the SURE-PD trial, consistent with the study's design and with preliminary evidence for slower clinical decline in early PD among women treated with urate-elevating doses of inosine. CLINICALTRIALSGOV IDENTIFIER: NCT00833690. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that inosine produced greater urate elevation in women than men and may slow PD progression in women.
RCT Entities:
OBJECTIVE: To investigate whether women and men with Parkinson disease (PD) differ in their biochemical and clinical responses to long-term treatment with inosine. METHODS: The Safety of Urate Elevation in Parkinson's Disease (SURE-PD) trial enrolled 75 people with early PD and baseline serum urate below 6 mg/dL and randomized them to 3 double-blinded treatment arms: oral placebo or inosine titrated to produce mild (6.1-7.0 mg/dL) or moderate (7.1-8.0 mg/dL) serum urate elevation for up to 2 years. Parkinsonism, serum urate, and plasma antioxidant capacity were measured at baseline and repeatedly on treatment; CSF urate was assessed once, at 3 months. Here in secondary analyses results are stratified by sex. RESULTS:Inosine produced an absolute increase in average serum urate from baseline that was 50% greater in women (3.0 mg/dL) than in men (2.0 mg/dL), consistent with expected lower baseline levels in women. Similarly, only among women was CSF urate significantly greater on mild or moderate inosine (+87% [p < 0.001] and +98% [p < 0.001], respectively) than on placebo (in contrast to men: +10% [p = 0.6] and +14% [p = 0.4], respectively). Women in the higher inosine dosing group showed a 7.0 Unified Parkinson's Disease Rating Scale (UPDRS) points/year lower rate of decline vs placebo (p = 0.01). In women, slower rates of UPDRS change were associated with greater increases in serum urate (r = -0.52; p = 0.001), and with greater increases in plasma antioxidant capacity (r = -0.44; p = 0.006). No significant associations were observed in men. CONCLUSIONS:Inosine produced greater increases in serum and CSF urate in women compared to men in the SURE-PD trial, consistent with the study's design and with preliminary evidence for slower clinical decline in early PD among women treated with urate-elevating doses of inosine. CLINICALTRIALSGOV IDENTIFIER: NCT00833690. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that inosine produced greater urate elevation in women than men and may slow PD progression in women.
Authors: Richard E Gonsette; Christian Sindic; Marie B D'hooghe; Peter-Paul De Deyn; Robert Medaer; Alex Michotte; Pierrette Seeldrayers; Daniel Guillaume Journal: Mult Scler Date: 2010-03-03 Impact factor: 6.312
Authors: Clyde E Markowitz; Sergei Spitsin; Vanessa Zimmerman; Dina Jacobs; Jayaram K Udupa; D Craig Hooper; Hilary Koprowski Journal: J Altern Complement Med Date: 2009-06 Impact factor: 2.579
Authors: Michael A Schwarzschild; Steven R Schwid; Kenneth Marek; Arthur Watts; Anthony E Lang; David Oakes; Ira Shoulson; Alberto Ascherio; Christopher Hyson; Emily Gorbold; Alice Rudolph; Karl Kieburtz; Stanley Fahn; Lisa Gauger; Christopher Goetz; John Seibyl; Misser Forrest; John Ondrasik Journal: Arch Neurol Date: 2008-04-14
Authors: Alberto Ascherio; Peter A LeWitt; Kui Xu; Shirley Eberly; Arthur Watts; Wayne R Matson; Connie Marras; Karl Kieburtz; Alice Rudolph; Mikhail B Bogdanov; Steven R Schwid; Marsha Tennis; Caroline M Tanner; M Flint Beal; Anthony E Lang; David Oakes; Stanley Fahn; Ira Shoulson; Michael A Schwarzschild Journal: Arch Neurol Date: 2009-12
Authors: M Moccia; M Picillo; R Erro; C Vitale; K Longo; M Amboni; G Santangelo; R Palladino; G Capo; G Orefice; P Barone; M T Pellecchia Journal: Eur J Neurol Date: 2014-08-07 Impact factor: 6.089
Authors: Michael A Schwarzschild; Alberto Ascherio; Cindy Casaceli; Gary C Curhan; Rebecca Fitzgerald; Cornelia Kamp; Codrin Lungu; Eric A Macklin; Kenneth Marek; Dariush Mozaffarian; David Oakes; Alice Rudolph; Ira Shoulson; Aleksandar Videnovic; Burton Scott; Lisa Gauger; Jason Aldred; Melissa Bixby; Jill Ciccarello; Steven A Gunzler; Claire Henchcliffe; Matthew Brodsky; Kellie Keith; Robert A Hauser; Christopher Goetz; Mark S LeDoux; Vanessa Hinson; Rajeev Kumar; Alberto J Espay; Joohi Jimenez-Shahed; Christine Hunter; Chadwick Christine; Aaron Daley; Maureen Leehey; J Antonelle de Marcaida; Joseph Harold Friedman; Albert Hung; Grace Bwala; Irene Litvan; David K Simon; Tanya Simuni; Cynthia Poon; Mya C Schiess; Kelvin Chou; Ariane Park; Danish Bhatti; Carolyn Peterson; Susan R Criswell; Liana Rosenthal; Jennifer Durphy; Holly A Shill; Shyamal H Mehta; Anwar Ahmed; Andres F Deik; John Y Fang; Natividad Stover; Lin Zhang; Richard B Dewey; Ashley Gerald; James T Boyd; Emily Houston; Valerie Suski; Sherri Mosovsky; Leslie Cloud; Binit B Shah; Marie Saint-Hilaire; Raymond James; Sarah Elizabeth Zauber; Stephen Reich; David Shprecher; Rajesh Pahwa; April Langhammer; Kathrin LaFaver; Peter A LeWitt; Patricia Kaminski; John Goudreau; Doozie Russell; David J Houghton; Ashley Laroche; Karen Thomas; Martha McGraw; Zoltan Mari; Carmen Serrano; Karen Blindauer; Marcie Rabin; Roger Kurlan; John C Morgan; Michael Soileau; Melissa Ainslie; Ivan Bodis-Wollner; Ruth B Schneider; Cheryl Waters; Amber Servi Ratel; Christopher A Beck; Patrick Bolger; Katherine F Callahan; Grace F Crotty; David Klements; Melissa Kostrzebski; Gearoid Michael McMahon; Lindsay Pothier; Sushrut S Waikar; Anthony Lang; Tiago Mestre Journal: JAMA Date: 2021-09-14 Impact factor: 56.272
Authors: Lindsay N Helget; Bryant R England; Punyasha Roul; Harlan Sayles; Alison D Petro; Tuhina Neogi; James R O'Dell; Ted R Mikuls Journal: Arthritis Care Res (Hoboken) Date: 2022-03-16 Impact factor: 5.178
Authors: Avi Goldberg; Fernando Garcia-Arroyo; Fumihiko Sasai; Bernardo Rodriguez-Iturbe; Laura Gabriela Sanchez-Lozada; Miguel A Lanaspa; Richard J Johnson Journal: Am J Nephrol Date: 2021-10-21 Impact factor: 4.605
Authors: Russell G Saltzman; Dushyantha T Jayaweera; Lina V Caceres; Jairo A Tovar; Mayra Vidro-Casiano; Vela Karakeshishyan; Jeanette Soto; Aisha Khan; Raul D Mitrani; Ivonne H Schulman; Joshua M Hare Journal: Contemp Clin Trials Commun Date: 2021-01-07
Authors: Laura G Sanchez-Lozada; Bernardo Rodriguez-Iturbe; Eric E Kelley; Takahiko Nakagawa; Magdalena Madero; Dan I Feig; Claudio Borghi; Federica Piani; Gabriel Cara-Fuentes; Petter Bjornstad; Miguel A Lanaspa; Richard J Johnson Journal: Am J Hypertens Date: 2020-07-18 Impact factor: 3.080
Authors: Rafael Franco; Rafael Rivas-Santisteban; Irene Reyes-Resina; Gemma Navarro; Eva Martínez-Pinilla Journal: Front Aging Neurosci Date: 2020-03-12 Impact factor: 5.750